# IMscin001 (NCT03735121)

> A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: subcutaneous atezolizumab
- Indication: previously treated locally advanced or metastatic NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03735121
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Atezolizumab; rHuPH20
- Enrollment: 438
- Primary outcome: Part 1: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1
- Primary outcome: Part 2: Observed Serum Ctrough of Atezolizumab at Cycle 1
- Primary outcome: Part 2: Area Under the Concentration-Time Curve From Time Zero to 21 Days (AUC 0-21 d) at Cycle 1

## Indexed commentary on IMscin001 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 12
- YouTube: 4
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=imscin001-nct03735121

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03735121", "email": "<work email>"}; the inbox owner confirms by the emailed link.